eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR – Get Rating) major shareholder Presidio Management Group X. Ll sold 26,703 shares of the firm’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $0.79, for a total transaction of $21,095.37. Following the transaction, the insider now directly owns 130,218 shares of the company’s stock, valued at approximately $102,872.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
eFFECTOR Therapeutics Trading Up 0.7 %
Shares of NASDAQ EFTR opened at $0.82 on Friday. eFFECTOR Therapeutics, Inc. has a twelve month low of $0.75 and a twelve month high of $40.42. The firm has a fifty day simple moving average of $1.32 and a 200 day simple moving average of $3.08. The company has a debt-to-equity ratio of 0.75, a current ratio of 18.38 and a quick ratio of 18.38.
eFFECTOR Therapeutics (NASDAQ:EFTR – Get Rating) last announced its earnings results on Tuesday, May 10th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.39. On average, equities research analysts predict that eFFECTOR Therapeutics, Inc. will post -0.52 EPS for the current fiscal year.
Analyst Ratings Changes
Hedge Funds Weigh In On eFFECTOR Therapeutics
Hedge funds have recently bought and sold shares of the company. State Street Corp bought a new position in eFFECTOR Therapeutics during the first quarter worth $68,000. Resolute Financial LLC acquired a new stake in eFFECTOR Therapeutics in the second quarter worth $43,000. Alps Advisors Inc. acquired a new stake in eFFECTOR Therapeutics in the fourth quarter worth $430,000. Parallel Advisors LLC acquired a new stake in eFFECTOR Therapeutics in the first quarter worth $2,744,000. Finally, OUP Management Co. LLC acquired a new stake in eFFECTOR Therapeutics in the fourth quarter worth $8,493,000. Institutional investors own 51.71% of the company’s stock.
About eFFECTOR Therapeutics
eFFECTOR Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on eFFECTOR Therapeutics (EFTR)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for eFFECTOR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eFFECTOR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.